Pliant Capital Expenditures vs Change To Netincome Analysis

PLRX Stock

USD 12.13 0.04 0.33%

Pliant TherapeuticsInc financial indicator trend analysis is much more than just breaking down Pliant TherapeuticsInc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pliant TherapeuticsInc is a good investment. Please check the relationship between Pliant TherapeuticsInc Capital Expenditures and its Change To Netincome accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant TherapeuticsInc guide.

Capital Expenditures vs Change To Netincome

Capital Expenditures vs Change To Netincome Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pliant TherapeuticsInc Capital Expenditures account and Change To Netincome. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Pliant TherapeuticsInc's Capital Expenditures and Change To Netincome is -0.17. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Change To Netincome in the same time period over historical financial statements of Pliant TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of Pliant TherapeuticsInc's Capital Expenditures and Change To Netincome is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Pliant TherapeuticsInc are associated (or correlated) with its Change To Netincome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Netincome has no effect on the direction of Capital Expenditures i.e., Pliant TherapeuticsInc's Capital Expenditures and Change To Netincome go up and down completely randomly.

Correlation Coefficient

-0.17

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Pliant TherapeuticsInc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pliant TherapeuticsInc operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Change To Netincome

Most indicators from Pliant TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pliant TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant TherapeuticsInc guide.Sales General And Administrative To Revenue is likely to rise to 38.50 in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	272K	4.7M	20.5M	21.5M
Net Interest Income	272K	3.9M	19.2M	20.2M

Interest Income Net Interest Income

Pliant TherapeuticsInc fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets
Total Assets		0.9	0.99	0.78	0.95	-0.96	0.69	0.66	1.0	0.54	0.31	1.0	0.89	0.6	0.76	0.92	0.5	0.47	0.6	-0.03	-0.26	0.98	0.93	-0.76	0.38	0.91
Total Current Liabilities	0.9		0.88	0.79	0.89	-0.91	0.72	0.61	0.89	0.4	0.31	0.9	0.98	0.66	0.92	0.99	0.63	0.62	0.71	-0.04	-0.19	0.91	0.95	-0.73	0.61	0.97
Total Stockholder Equity	0.99	0.88		0.69	0.98	-0.95	0.69	0.54	0.99	0.47	0.14	0.99	0.9	0.57	0.76	0.9	0.51	0.54	0.56	-0.17	-0.39	0.99	0.89	-0.84	0.38	0.9
Other Liab	0.78	0.79	0.69		0.68	-0.68	0.59	0.94	0.77	0.69	0.7	0.77	0.71	0.76	0.6	0.77	0.49	0.3	0.64	0.32	0.19	0.68	0.84	-0.5	0.46	0.8
Net Tangible Assets	0.95	0.89	0.98	0.68		-0.91	0.63	0.49	0.95	0.48	0.07	0.95	0.92	0.6	0.79	0.9	0.59	0.66	0.61	-0.22	-0.41	0.97	0.87	-0.9	0.49	0.93
Retained Earnings	-0.96	-0.91	-0.95	-0.68	-0.91		-0.74	-0.56	-0.96	-0.31	-0.26	-0.96	-0.9	-0.57	-0.84	-0.92	-0.54	-0.51	-0.63	0.09	0.33	-0.98	-0.9	0.72	-0.43	-0.89
Accounts Payable	0.69	0.72	0.69	0.59	0.63	-0.74		0.51	0.69	0.14	0.14	0.69	0.71	0.6	0.52	0.67	0.26	0.25	0.34	-0.23	-0.39	0.66	0.69	-0.62	0.26	0.69
Cash	0.66	0.61	0.54	0.94	0.49	-0.56	0.51		0.65	0.73	0.85	0.66	0.49	0.67	0.37	0.59	0.28	-0.03	0.5	0.55	0.4	0.51	0.73	-0.25	0.24	0.61
Cash And Short Term Investments	1.0	0.89	0.99	0.77	0.95	-0.96	0.69	0.65		0.53	0.3	1.0	0.89	0.59	0.76	0.91	0.49	0.47	0.59	-0.04	-0.27	0.98	0.92	-0.76	0.37	0.9
Net Receivables	0.54	0.4	0.47	0.69	0.48	-0.31	0.14	0.73	0.53		0.52	0.54	0.36	0.37	0.11	0.42	0.07	-0.07	0.24	0.5	0.41	0.38	0.6	-0.27	0.01	0.47
Total Liab	0.31	0.31	0.14	0.7	0.07	-0.26	0.14	0.85	0.3	0.52		0.3	0.16	0.35	0.18	0.31	0.08	-0.28	0.34	0.79	0.7	0.17	0.44	0.24	0.08	0.25
Total Current Assets	1.0	0.9	0.99	0.77	0.95	-0.96	0.69	0.66	1.0	0.54	0.3		0.89	0.59	0.76	0.91	0.49	0.47	0.59	-0.03	-0.26	0.98	0.93	-0.76	0.37	0.9
Common Stock	0.89	0.98	0.9	0.71	0.92	-0.9	0.71	0.49	0.89	0.36	0.16	0.89		0.56	0.91	0.98	0.57	0.68	0.61	-0.2	-0.34	0.92	0.92	-0.79	0.54	0.95
Property Plant Equipment	0.6	0.66	0.57	0.76	0.6	-0.57	0.6	0.67	0.59	0.37	0.35	0.59	0.56		0.54	0.61	0.79	0.37	0.85	0.15	0.06	0.56	0.64	-0.61	0.77	0.76
Short Long Term Debt Total	0.76	0.92	0.76	0.6	0.79	-0.84	0.52	0.37	0.76	0.11	0.18	0.76	0.91	0.54		0.92	0.75	0.78	0.77	-0.16	-0.28	0.85	0.78	-0.66	0.73	0.87
Other Current Liab	0.92	0.99	0.9	0.77	0.9	-0.92	0.67	0.59	0.91	0.42	0.31	0.91	0.98	0.61	0.92		0.61	0.61	0.7	-0.03	-0.19	0.93	0.96	-0.72	0.57	0.97
Property Plant And Equipment Net	0.5	0.63	0.51	0.49	0.59	-0.54	0.26	0.28	0.49	0.07	0.08	0.49	0.57	0.79	0.75	0.61		0.73	0.95	-0.07	-0.12	0.58	0.48	-0.62	0.97	0.71
Net Debt	0.47	0.62	0.54	0.3	0.66	-0.51	0.25	-0.03	0.47	-0.07	-0.28	0.47	0.68	0.37	0.78	0.61	0.73		0.55	-0.59	-0.58	0.61	0.39	-0.77	0.72	0.63
Non Current Assets Total	0.6	0.71	0.56	0.64	0.61	-0.63	0.34	0.5	0.59	0.24	0.34	0.59	0.61	0.85	0.77	0.7	0.95	0.55		0.2	0.1	0.63	0.64	-0.53	0.92	0.78
Non Currrent Assets Other	-0.03	-0.04	-0.17	0.32	-0.22	0.09	-0.23	0.55	-0.04	0.5	0.79	-0.03	-0.2	0.15	-0.16	-0.03	-0.07	-0.59	0.2		0.95	-0.16	0.17	0.53	-0.06	-0.05
Other Assets	-0.26	-0.19	-0.39	0.19	-0.41	0.33	-0.39	0.4	-0.27	0.41	0.7	-0.26	-0.34	0.06	-0.28	-0.19	-0.12	-0.58	0.1	0.95		-0.38	-0.02	0.63	-0.05	-0.2
Common Stock Total Equity	0.98	0.91	0.99	0.68	0.97	-0.98	0.66	0.51	0.98	0.38	0.17	0.98	0.92	0.56	0.85	0.93	0.58	0.61	0.63	-0.16	-0.38		0.89	-0.81	0.46	0.91
Common Stock Shares Outstanding	0.93	0.95	0.89	0.84	0.87	-0.9	0.69	0.73	0.92	0.6	0.44	0.93	0.92	0.64	0.78	0.96	0.48	0.39	0.64	0.17	-0.02	0.89		-0.63	0.44	0.94
Non Current Liabilities Total	-0.76	-0.73	-0.84	-0.5	-0.9	0.72	-0.62	-0.25	-0.76	-0.27	0.24	-0.76	-0.79	-0.61	-0.66	-0.72	-0.62	-0.77	-0.53	0.53	0.63	-0.81	-0.63		-0.55	-0.81
Capital Lease Obligations	0.38	0.61	0.38	0.46	0.49	-0.43	0.26	0.24	0.37	0.01	0.08	0.37	0.54	0.77	0.73	0.57	0.97	0.72	0.92	-0.06	-0.05	0.46	0.44	-0.55		0.67
Other Current Assets	0.91	0.97	0.9	0.8	0.93	-0.89	0.69	0.61	0.9	0.47	0.25	0.9	0.95	0.76	0.87	0.97	0.71	0.63	0.78	-0.05	-0.2	0.91	0.94	-0.81	0.67

Click cells to compare fundamentals

Pliant TherapeuticsInc Account Relationship Matchups

Pliant TherapeuticsInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	119.1M	295.5M	221.2M	350.6M	512.2M	537.8M
Total Current Liabilities	8.2M	11.6M	16.8M	23.9M	28.5M	15.3M
Total Stockholder Equity	(435K)	283.1M	199.1M	313.3M	473.6M	497.3M
Net Tangible Assets	(76.3M)	283.1M	199.1M	313.3M	360.3M	378.4M
Retained Earnings	(76.3M)	(117.8M)	(215.1M)	(338.4M)	(499.7M)	(474.8M)
Accounts Payable	1.3M	2.0M	3.0M	1.6M	4.5M	2.6M
Cash	85.8M	50.9M	51.7M	33.7M	63.2M	55.1M
Cash And Short Term Investments	102.8M	276.9M	200.6M	331.2M	494.2M	519.0M
Net Receivables	7.4M	9.4M	2.1M	2.1M	3.0M	3.9M
Total Liab	119.5M	12.5M	22.2M	37.3M	38.6M	34.4M
Total Current Assets	111.9M	290.8M	209.4M	340.3M	505.5M	530.8M
Property Plant Equipment	4.1M	4.3M	10.9M	4.5M	5.2M	5.5M
Short Long Term Debt Total	444K	283K	7.2M	15.8M	11.4M	6.5M
Other Current Liab	6.9M	9.6M	12.0M	19.9M	22.7M	13.5M
Property Plant And Equipment Net	4.1M	4.3M	10.9M	9.9M	4.8M	7.0M
Net Debt	(85.4M)	(50.6M)	(44.5M)	(17.9M)	(51.9M)	(54.5M)
Non Current Assets Total	7.2M	4.8M	11.8M	10.3M	6.7M	8.3M
Non Currrent Assets Other	3.1M	451K	838K	394K	392.0K	759.5K
Other Assets	3.1M	451K	838K	394K	1.0	0.95
Common Stock Shares Outstanding	35.6M	35.6M	35.8M	42.0M	58.7M	41.1M
Short Term Investments	17.0M	226.0M	148.9M	297.5M	431.0M	452.6M
Liabilities And Stockholders Equity	119.1M	295.5M	221.2M	350.6M	512.2M	286.9M
Non Current Liabilities Total	111.3M	866K	5.3M	13.4M	10.1M	9.6M
Capital Lease Obligations	444K	283K	7.2M	5.9M	1.3M	1.3M
Other Current Assets	1.7M	4.5M	6.8M	7.1M	8.3M	5.2M
Other Stockholder Equity	2.2M	105.4M	414.3M	653.7M	973.0M	1.0B
Net Invested Capital	(76.3M)	283.1M	199.1M	323.3M	483.6M	507.8M
Accumulated Other Comprehensive Income	(1K)	(32K)	(201K)	(2.0M)	345K	362.3K
Non Current Liabilities Other	10K	2K	5.3M	3.4M	3.9M	4.1M
Net Working Capital	103.7M	279.2M	192.6M	316.4M	477.0M	261.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Pliant TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pliant TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pliant Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pliant Therapeuticsinc Stock:

How To Invest In Pliant

Details

Is Pliant Stock a good investment?

Details

What is Pliant TherapeuticsInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant TherapeuticsInc guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Pliant Stock analysis

When running Pliant TherapeuticsInc's price analysis, check to measure Pliant TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant TherapeuticsInc is operating at the current time. Most of Pliant TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Pliant TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant TherapeuticsInc's price. Additionally, you may evaluate how the addition of Pliant TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.

	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Fundamental Analysis View fundamental data based on most recent published financial statements

Is Pliant TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant TherapeuticsInc. If investors know Pliant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pliant TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.86)

Revenue Per Share

0.004

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.22)

Return On Equity

(0.34)

The market value of Pliant TherapeuticsInc is measured differently than its book value, which is the value of Pliant that is recorded on the company's balance sheet. Investors also form their own opinion of Pliant TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Pliant TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pliant TherapeuticsInc's market value can be influenced by many factors that don't directly affect Pliant TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pliant TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pliant TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pliant TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pliant Capital Expenditures vs Change To Netincome Analysis

Capital Expenditures vs Change To Netincome

Capital Expenditures vs Change To Netincome Correlation Analysis

Correlation Coefficient

Capital Expenditures

Change To Netincome

Pliant TherapeuticsInc fundamental ratios Correlations

Pliant TherapeuticsInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pliant TherapeuticsInc fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Pliant Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Other Current Liab	+ 0.99	Total Current Liabilities
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Common Stock Total Equity	- 0.98	Retained Earnings
Total Current Assets	- 0.96	Retained Earnings
Cash And Short Term Investments	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Assets
Retained Earnings	- 0.95	Total Stockholder Equity
Other Current Liab	- 0.92	Retained Earnings